Hologic, Inc. (HOLX) EV/FCF Ratio: 17.53x
Is Hologic, Inc.’s EV/FCF ratio high or low?
Hologic, Inc.'s EV/FCF ratio of 17.53x is 16% above its 5-year average of 15.13x, around the middle of its 5-year range (6.92x–25.30x).
The EV/FCF ratio for Hologic, Inc. (HOLX) is 17.53x as of Wednesday, June 10, 2026. It is above its 12-month average by 3.79% (16.89x).
HOLX EV/FCF Ratio Chart
HOLX Average EV/FCF Ratio Chart
HOLX Current vs Average EV/FCF Ratio Chart
HOLX EV/FCF Ratio Metrics
EV/FCF RATIO
17.53x
EV/FCF RATIO AVG TTM
16.89x
EV/FCF RATIO AVG 3Y
18.61x
EV/FCF RATIO AVG 5Y
15.13x
EV/FCF RATIO AVG 10Y
19.80x
EV/FCF RATIO AVG 15Y
21.06x
EV/FCF RATIO AVG 20Y
35.47x
CURRENT VS TTM AVG
+3.79%
CURRENT VS 3Y AVG
-5.82%
CURRENT VS 5Y AVG
+15.89%
CURRENT VS 10Y AVG
-11.47%
CURRENT VS 15Y AVG
-16.78%
CURRENT VS 20Y AVG
-50.58%
HOLX Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | — | 17.53x | 16.89x | 18.61x | 15.13x |
| Moderna, Inc. (MRNA) | $18.40B | N/A | 26.90x | 26.23x | 26.23x |
| Align Technology, Inc. (ALGN) | $12.56B | 16.92x | 17.72x | 29.59x | 38.96x |
| BioNTech SE (BNTX) | $21.81B | 7.13x | 22.05x | 6.21x | 11.27x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 31.65x | 33.77x | 33.51x | 38.38x |
| Waters Corporation (WAT) | $23.83B | 133.18x | 43.36x | 43.04x | 41.43x |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 30.84x | 21.24x | 29.09x | 35.23x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 24.48x | 25.09x | 43.47x | 51.10x |
| Veeva Systems Inc. (VEEV) | $26.73B | 48.97x | 29.32x | 32.91x | 38.27x |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | 98.69x | 83.00x | 71.55x | 71.55x |
Cash Flow Valuation Comparison
EV/FCF
17.5x
P/FCF
17.2x
FCF Yield
5.82%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Hologic, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Hologic, Inc. (HOLX)?
- The EV/FCF ratio for HOLX stock is 17.53x.
- Is Hologic, Inc.'s EV/FCF ratio high or low?
- Hologic, Inc.'s EV/FCF ratio of 17.53x is 16% above its 5-year average of 15.13x, around the middle of its 5-year range (6.92x–25.30x).
- What is the TTM average EV/FCF ratio for Hologic, Inc. (HOLX)?
- The TTM average EV/FCF ratio for HOLX stock is 16.89x.
- What is the 3Y average EV/FCF ratio for Hologic, Inc. (HOLX)?
- The 3Y average EV/FCF ratio for HOLX stock is 18.61x.
- What is the 5Y average EV/FCF ratio for Hologic, Inc. (HOLX)?
- The 5Y average EV/FCF ratio for HOLX stock is 15.13x.
- What is the 10Y average EV/FCF ratio for Hologic, Inc. (HOLX)?
- The 10Y average EV/FCF ratio for HOLX stock is 19.80x.
- What is the 15Y average EV/FCF ratio for Hologic, Inc. (HOLX)?
- The 15Y average EV/FCF ratio for HOLX stock is 21.06x.
- What is the 20Y average EV/FCF ratio for Hologic, Inc. (HOLX)?
- The 20Y average EV/FCF ratio for HOLX stock is 35.47x.
Hologic, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-04-07 | 17.53x |
| 2026-04-06 | 17.53x |
| 2026-04-02 | 17.45x |
| 2026-04-01 | 17.44x |
| 2026-03-31 | 17.43x |
| 2026-03-30 | 17.42x |
| 2026-03-27 | 17.45x |
| 2026-03-26 | 17.46x |
| 2026-03-25 | 17.42x |
| 2026-03-24 | 17.42x |
| 2026-03-23 | 17.44x |
| 2026-03-20 | 17.39x |
| 2026-03-19 | 17.37x |
| 2026-03-18 | 17.33x |
| 2026-03-17 | 17.31x |
| 2026-03-16 | 17.33x |
| 2026-03-13 | 17.33x |
| 2026-03-12 | 17.35x |
| 2026-03-11 | 17.39x |
| 2026-03-10 | 17.42x |
| 2026-03-09 | 17.43x |
| 2026-03-06 | 17.47x |
| 2026-03-05 | 17.47x |
| 2026-03-04 | 17.45x |
| 2026-03-03 | 17.40x |
| 2026-03-02 | 17.40x |
| 2026-02-27 | 17.38x |
| 2026-02-26 | 17.35x |
| 2026-02-25 | 17.38x |
| 2026-02-24 | 17.38x |
| 2026-02-23 | 17.40x |
| 2026-02-20 | 17.40x |
| 2026-02-19 | 17.33x |
| 2026-02-18 | 17.35x |
| 2026-02-17 | 17.33x |
| 2026-02-13 | 17.31x |
| 2026-02-12 | 17.28x |
| 2026-02-11 | 17.32x |
| 2026-02-10 | 17.33x |
| 2026-02-09 | 17.30x |
| 2026-02-06 | 17.26x |
| 2026-02-05 | 17.23x |
| 2026-02-04 | 17.21x |
| 2026-02-03 | 17.22x |
| 2026-02-02 | 17.24x |
| 2026-01-30 | 17.28x |
| 2026-01-29 | 17.30x |
| 2026-01-28 | 19.01x |
| 2026-01-27 | 19.04x |
| 2026-01-26 | 19.04x |
| 2026-01-23 | 19.00x |
| 2026-01-22 | 19.02x |
| 2026-01-21 | 19.02x |
| 2026-01-20 | 19.02x |
| 2026-01-16 | 18.98x |
| 2026-01-15 | 18.99x |
| 2026-01-14 | 19.03x |
| 2026-01-13 | 18.96x |
| 2026-01-12 | 18.95x |
| 2026-01-09 | 18.96x |
| 2026-01-08 | 18.96x |
| 2026-01-07 | 18.98x |
| 2026-01-06 | 18.97x |
| 2026-01-05 | 18.93x |
| 2026-01-02 | 18.88x |
| 2025-12-31 | 18.86x |
| 2025-12-30 | 18.88x |
| 2025-12-29 | 18.87x |
| 2025-12-26 | 18.87x |
| 2025-12-24 | 18.87x |
| 2025-12-23 | 18.96x |
| 2025-12-22 | 18.97x |
| 2025-12-19 | 18.98x |
| 2025-12-18 | 18.97x |
| 2025-12-17 | 18.97x |
| 2025-12-16 | 18.99x |
| 2025-12-15 | 19.04x |
| 2025-12-12 | 18.99x |
| 2025-12-11 | 18.95x |
| 2025-12-10 | 18.95x |
| 2025-12-09 | 18.96x |
| 2025-12-08 | 18.95x |
| 2025-12-05 | 18.98x |
| 2025-12-04 | 18.95x |
| 2025-12-03 | 18.99x |
| 2025-12-02 | 18.95x |
| 2025-12-01 | 18.95x |
| 2025-11-28 | 18.98x |
| 2025-11-26 | 18.94x |
| 2025-11-25 | 18.96x |
| 2025-11-24 | 18.93x |
| 2025-11-21 | 18.83x |
| 2025-11-20 | 18.77x |
| 2025-11-19 | 18.79x |
| 2025-11-18 | 18.77x |
| 2025-11-17 | 18.65x |
| 2025-11-14 | 18.65x |
| 2025-11-13 | 18.67x |
| 2025-11-12 | 18.75x |
| 2025-11-11 | 18.76x |
| 2025-11-10 | 18.68x |
| 2025-11-07 | 18.64x |
| 2025-11-06 | 18.65x |
| 2025-11-05 | 18.67x |
| 2025-11-04 | 18.64x |
| 2025-11-03 | 18.63x |
| 2025-10-31 | 18.59x |
| 2025-10-30 | 18.60x |
| 2025-10-29 | 18.61x |
| 2025-10-28 | 18.61x |
| 2025-10-27 | 18.60x |
| 2025-10-24 | 18.61x |
| 2025-10-23 | 18.59x |
| 2025-10-22 | 18.60x |
| 2025-10-21 | 18.61x |
| 2025-10-20 | 18.10x |
| 2025-10-17 | 17.62x |
| 2025-10-16 | 17.29x |
| 2025-10-15 | 16.93x |
| 2025-10-14 | 16.67x |
| 2025-10-13 | 16.57x |
| 2025-10-10 | 17.11x |
| 2025-10-09 | 17.32x |
| 2025-10-08 | 17.25x |
| 2025-10-07 | 17.11x |
| 2025-10-06 | 17.01x |
| 2025-10-03 | 17.22x |
| 2025-10-02 | 17.15x |
| 2025-10-01 | 16.94x |
| 2025-09-30 | 17.05x |
| 2025-09-29 | 16.97x |
| 2025-09-26 | 16.98x |
| 2025-09-25 | 16.64x |
| 2025-09-24 | 16.79x |
| 2025-09-23 | 17.08x |
| 2025-09-22 | 17.00x |
| 2025-09-19 | 16.77x |
| 2025-09-18 | 17.24x |
| 2025-09-17 | 17.22x |
| 2025-09-16 | 16.05x |
| 2025-09-15 | 16.16x |
| 2025-09-12 | 16.32x |
| 2025-09-11 | 16.78x |
| 2025-09-10 | 16.57x |
| 2025-09-09 | 16.86x |
| 2025-09-08 | 16.82x |
| 2025-09-05 | 16.87x |
| 2025-09-04 | 16.78x |
| 2025-09-03 | 16.75x |
| 2025-09-02 | 16.84x |
| 2025-08-29 | 16.96x |
| 2025-08-28 | 16.84x |
| 2025-08-27 | 16.87x |
| 2025-08-26 | 16.84x |
| 2025-08-25 | 16.96x |
| 2025-08-22 | 17.23x |
| 2025-08-21 | 16.97x |
| 2025-08-20 | 17.35x |
| 2025-08-19 | 17.13x |
| 2025-08-18 | 17.00x |
| 2025-08-15 | 17.13x |
| 2025-08-14 | 17.19x |
| 2025-08-13 | 17.41x |
| 2025-08-12 | 17.16x |
| 2025-08-11 | 17.17x |
| 2025-08-08 | 17.19x |
| 2025-08-07 | 17.15x |
| 2025-08-06 | 16.90x |
| 2025-08-05 | 17.13x |
| 2025-08-04 | 17.15x |
| 2025-08-01 | 16.97x |
| 2025-07-31 | 16.89x |
| 2025-07-30 | 16.09x |
| 2025-07-29 | 16.34x |
| 2025-07-28 | 16.26x |
| 2025-07-25 | 16.44x |
| 2025-07-24 | 16.35x |
| 2025-07-23 | 16.32x |
| 2025-07-22 | 16.18x |
| 2025-07-21 | 15.80x |
| 2025-07-18 | 15.86x |
| 2025-07-17 | 15.87x |
| 2025-07-16 | 15.83x |
| 2025-07-15 | 15.70x |
| 2025-07-14 | 16.01x |
| 2025-07-11 | 16.26x |
| 2025-07-10 | 16.52x |
| 2025-07-09 | 16.29x |
| 2025-07-08 | 16.07x |
| 2025-07-07 | 15.95x |
| 2025-07-03 | 16.05x |
| 2025-07-02 | 16.17x |
| 2025-07-01 | 16.17x |
| 2025-06-30 | 16.13x |
| 2025-06-27 | 16.10x |
| 2025-06-26 | 16.12x |
| 2025-06-25 | 15.93x |
| 2025-06-24 | 16.06x |
| 2025-06-23 | 15.97x |
| 2025-06-20 | 15.98x |
| 2025-06-18 | 15.86x |
| 2025-06-17 | 15.90x |
| 2025-06-16 | 16.14x |
| 2025-06-13 | 16.04x |
| 2025-06-12 | 16.15x |
| 2025-06-11 | 16.00x |
| 2025-06-10 | 16.13x |
| 2025-06-09 | 16.00x |
| 2025-06-06 | 15.94x |
| 2025-06-05 | 15.65x |
| 2025-06-04 | 15.54x |
| 2025-06-03 | 15.65x |
| 2025-06-02 | 15.41x |
| 2025-05-30 | 15.45x |
| 2025-05-29 | 15.62x |
| 2025-05-28 | 15.80x |
| 2025-05-27 | 15.45x |
| 2025-05-23 | 13.63x |
| 2025-05-22 | 13.67x |
| 2025-05-21 | 13.75x |
| 2025-05-20 | 14.13x |
| 2025-05-19 | 14.12x |
| 2025-05-16 | 14.21x |
| 2025-05-15 | 13.96x |
| 2025-05-14 | 13.88x |
| 2025-05-13 | 14.28x |
| 2025-05-12 | 14.67x |
| 2025-05-09 | 14.20x |
| 2025-05-08 | 14.07x |
| 2025-05-07 | 13.89x |
| 2025-05-06 | 13.36x |
| 2025-05-05 | 13.27x |
| 2025-05-02 | 13.60x |
| 2025-05-01 | 12.60x |
| 2025-04-30 | 12.79x |
| 2025-04-29 | 12.83x |
| 2025-04-28 | 12.77x |
| 2025-04-25 | 12.75x |
| 2025-04-24 | 12.81x |
| 2025-04-23 | 12.78x |
| 2025-04-22 | 12.79x |
| 2025-04-21 | 12.53x |
| 2025-04-17 | 12.66x |
| 2025-04-16 | 12.44x |
| 2025-04-15 | 12.72x |
| 2025-04-14 | 12.93x |
| 2025-04-11 | 12.72x |
| 2025-04-10 | 12.58x |
| 2025-04-09 | 13.02x |
| 2025-04-08 | 12.85x |
| 2025-04-07 | 13.43x |
| 2025-04-04 | 13.35x |
| 2025-04-03 | 13.52x |
| 2025-04-02 | 13.28x |
| 2025-04-01 | 13.45x |
| 2025-03-31 | 13.53x |
| 2025-03-28 | 13.44x |
| 2025-03-27 | 13.65x |
| 2025-03-26 | 13.47x |
| 2025-03-25 | 13.33x |
Showing the most recent 260 of 4,681 data points. The chart above shows the full history.
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini